Eris Lifesciences Limited — Q4 FY25 earnings call

Call held 19 May 2025

Management summary

ERIS delivered a strong Q4 and full-year FY25 performance, characterized by robust revenue growth and substantial margin expansion following the integration of Biocon and Swiss Parenterals. The company is successfully transitioning to in-house manufacturing, aiming for 80% in-house production by the end of FY26. With a clear focus on the 'Diabesity' segment and a strong pipeline of GLP-1 and Insulin analogs, ERIS is positioning itself to become the #3 player in the Indian anti-diabetes market within three years.

Highlights

  • Consolidated Revenue for Q4 FY25 reached ₹705 crores, representing a 28% YoY growth.

  • Consolidated EBITDA stood at ₹252 crores, a significant 70% YoY increase with a 36% margin.

  • Full-year FY25 Revenue was ₹2,894 crores with EBITDA of ₹1,117 crores (51% growth).

  • Domestic Branded Formulations (DBF) delivered ₹2,513 crores in FY25, up 32% YoY.

  • Biocon business margins expanded to 24% in FY25, up from 19% at the time of acquisition.

  • Net Debt reduced to ₹2,200 crores, beating previous guidance by nearly ₹400 crores.

  • Management guided for FY26 Consolidated Revenue of ₹3,325-3,500 crores (15-21% growth).

  • Targeting a 50% growth in EPS for FY26 driven by margin expansion and debt reduction.

Key financials

  1. Revenue ₹705 Cr +28%YoY
  2. EBITDA ₹252 Cr +70%YoY
  3. EBITDA Margin 36%
  4. PAT ₹102 Cr +28%YoY
  5. Cash EPS ₹40 +5.2%YoY
  6. Net Debt ₹2,200 Cr

What they filed

Q1 FY27: revenue down 23.3%, net profit down 52.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue437 400 405 579 650 +49%315 −21%277 −32%444 −23%
EBITDA143 100 121 216 297 +108%77 −23%22 −82%120 −44%
Net profit28 2 30 100 150 +436%3 +50%-9 −130%48 −52%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue (FY25)
₹3,225 Cr Total
  • Domestic Branded Formulations (DBF) ₹2,513 Cr 77.9%
  • Biocon-2 (Acquired Franchise) ₹386 Cr 12.0%
  • Swiss Parenterals ₹326 Cr 10.1%

Guidance & targets

Revenue

  • Consolidated Revenue Revenue · FY26 · High confidence ₹3,325 - 3,500 crores
    Consolidated revenue in the range of Rs. 3,325 crores to Rs. 3,500 crores, which represents a growth of 15% to 21%.

    — V. Krishnakumar, COO

  • Human Insulin Cartridge Opportunity Revenue · FY26 · Medium confidence ₹200 - 300 crores
    We believe that we can take Rs. 200 crores to Rs. 300 crores per annum of this opportunity starting the second half of this financial year.

    — V. Krishnakumar, COO

Margin

  • Consolidated EBITDA Margin Margin · FY26 · High confidence 36%
    Consolidated EBITDA of Rs. 1,190 crores to Rs. 1,255 crores, which represents a 36% margin.

    — V. Krishnakumar, COO

Profitability

  • EPS Growth Profitability · FY26 · Medium confidence 50%
    We are guiding to a consolidated EPS growth of 50% and a Return on Capital of 22% adjusted.

    — V. Krishnakumar, COO

Debt

  • Net Debt Debt · FY26 · High confidence ₹1,800 crores
    From here on, we are looking at getting to Rs. 1,800 crores of Net Debt, which would be around 1.5x Debt to EBITDA by the end of the current financial year.

    — V. Krishnakumar, COO

Capex

  • Annual Capex Capex · FY26 · High confidence ₹200 crores
    At this point, we are looking at a capex of Rs. 200 crores in this financial year.

    — V. Krishnakumar, COO

Risks & concerns

  • Human Insulin Supply Continuity

    medium

    Management noted a ₹50 crore sales loss in FY25 due to shortages; while DS is secured, DP (Finished Product) supply remains a work in progress until Bhopal is fully licensed.

    Both acknowledged

  • Regulatory Delays in Bhopal Facility

    medium

    Licensing for cartridges will follow vials later in the year; any delay could impact the H2 FY26 revenue targets for the Insulin segment.

    Management acknowledged

  • Product Returns from Banned FDCs and At-Risk Launches

    low

    Management expects ₹60 crores in returns due to banned FDCs and the Linares E launch, which is factored into the FY26 guidance.

    Management acknowledged

Areas of evasion (1)

  • Specific unit capacity numbers for vials and cartridges in Bhopal were not provided despite being asked.

Q&A highlights

2 direct
Insulin Supply Shortages and DS/DP Security Direct
We have reasonable quantity of DS as of now... We feel that the markets would be able to sustain till July, August with current inventory. Post that, we will see the shortfall coming in. I was talking to you that the DS has been secured this time.

Investors were concerned about the ₹50 crore sales loss in FY25 due to supply issues; management confirms they have secured Drug Substance (DS) to mitigate this risk in FY26.

Asked by Kunal Dhamesha, Macquarie

Market Gap from Novo Nordisk's Exit Direct
Substitutes are either going back to the vials or it's around 4x of the monthly therapy cost... which we think is a stress to the patient. Our belief is whatever shift had to happen would have most likely happened.

Management identifies a significant opportunity in the Human Insulin cartridge market vacated by the innovator, which they plan to capture with their own brands.

Asked by Abhigyan Srivastav, Marcellus Investment Managers

Critical Care Segment Performance and Strategy Partial
Our go-to market didn't work. We had a little bit of a bandwidth issue... we had to improve the margins. We had to take out the products which were not giving us a lot of gross margins out and then develop the newer products with higher margins.

Explains the 20% planned decline in Critical Care as a strategic move to exit low-margin products and reset the business for better profitability in FY26.

Asked by Yash Mehta, Malabar

2 min read 5 chapters

Detailed narrative

Diabesity Strategy and GLP-1 Pipeline

ERIS is aggressively pursuing the 'Diabesity' market, targeting a #3 rank in the anti-diabetes segment within three years. The company launched Liraglutide for diabetes in September 2024 and is now targeting the first generic launch for obesity (Saxenda) in H1 FY26. Management believes their position as an insulin company gives them a 'right to win' in GLPs due to physician affinity. Further launches, including Semaglutide, are scheduled for FY27 and FY28.

Biocon Integration and Margin Expansion

The Biocon business integration has been successful, with margins expanding from 19% at acquisition to 24% in FY25, and exceeding 25% in Q4. This was achieved despite a ₹38 crore sales loss in the Biocon-2 segment due to global insulin shortages. Management expects further margin expansion in FY26 as insulin in-sourcing commences at the Bhopal facility, targeting a 37% EBITDA margin for the DBF segment.

Manufacturing In-sourcing and Bhopal Facility

A key driver for future margins is the shift to in-house production. In-house manufacturing stood at 66% in March 2025, up from less than 50% in April 2024, with a target to reach 80% by the end of FY26. The Bhopal facility is nearing the licensing stage for vial manufacturing, with cartridge production expected to follow in the second half of the year, enabling ERIS to capture the ₹450 crore market gap left by innovator exits.

Swiss Parenterals and International Expansion

Swiss Parenterals delivered ₹326 crores in revenue for FY25 with a 33.4% EBITDA margin. ERIS is leveraging Swiss's global distribution to export its OSD portfolio, with Anvisa inspections already completed for both Ahmedabad and Swiss facilities. Management guides for 15-20% revenue growth for Swiss in FY26, with a target to commence shipments to Brazil and other regulated markets in the final quarter.

Debt Reduction and Capital Allocation

ERIS demonstrated strong cash flow generation, with an operating cash flow to EBITDA ratio of 111% in Q4. Net debt ended the year at ₹2,200 crores, significantly lower than the guided ₹2,600 crores. The company plans to further reduce net debt to ₹1,800 crores by the end of FY26, achieving a 1.5x Debt-to-EBITDA ratio while maintaining a ₹200 crore capex program for injectable blocks and GLP validation.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls